CliffBio
small molecule

DENTIPATCH

LIDOCAINE

Loss of exclusivity—loss of exclusivity
CompanyNoven Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameDENTIPATCH
Active ingredientLIDOCAINE
Strength46.1MG/PATCH
Dosage formPATCH
RouteTOPICAL
ModalitySmall molecule
FDA approvalMay 1996
Marketing statusDISCN

More from Noven Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.